FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

Norman L. Foster, Judith L. Heidebrink, Christopher M. Clark, William J. Jagust, Steven E. Arnold, Nancy R. Barbas, Charles DeCarli, R. Scott Turner, Robert A. Koeppe, Roger Higdon, Satoshi Minoshima

Research output: Contribution to journalArticle

347 Citations (Scopus)

Abstract

Distinguishing Alzheimer's disease (AD) and frontotemporal dementia (FTD) currently relies on a clinical history and examination, but positron emission tomography with [18F] fluorodeoxyglucose (FDG-PET) shows different patterns of hypometabolism in these disorders that might aid differential diagnosis. Six dementia experts with variable FDG-PET experience made independent, forced choice, diagnostic decisions in 45 patients with pathologically confirmed AD (n = 31) or FTD (n = 14) using five separate methods: (1) review of clinical summaries, (2) a diagnostic checklist alone, (3) summary and checklist, (4) transaxial FDG-PET scans and (5) FDG-PET stereotactic surface projection (SSP) metabolic and statistical maps. In addition, we evaluated the effect of the sequential review of a clinical summary followed by SSP. Visual interpretation of SSP images was superior to clinical assessment and had the best inter-rater reliability (mean kappa = 0.78) and diagnostic accuracy (89.6%). It also had the highest specificity (97.6%) and sensitivity (86%), and positive likelihood ratio for FTD (36.5). The addition of FDG-PET to clinical summaries increased diagnostic accuracy and confidence for both AD and FTD. It was particularly helpful when raters were uncertain in their clinical diagnosis. Visual interpretation of FDG-PET after brief training is more reliable and accurate in distinguishing FTD from AD than clinical methods alone. FDG-PET adds important information that appropriately increases diagnostic confidence, even among experienced dementia specialists.

Original languageEnglish (US)
Pages (from-to)2616-2635
Number of pages20
JournalBrain
Volume130
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

Frontotemporal Dementia
Alzheimer Disease
Fluorodeoxyglucose F18
Checklist
Positron-Emission Tomography
Dementia
Differential Diagnosis
Sensitivity and Specificity

Keywords

  • Alzheimer's disease
  • FDG
  • Frontotemporal dementia
  • PET

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., ... Minoshima, S. (2007). FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 130(10), 2616-2635. https://doi.org/10.1093/brain/awm177

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. / Foster, Norman L.; Heidebrink, Judith L.; Clark, Christopher M.; Jagust, William J.; Arnold, Steven E.; Barbas, Nancy R.; DeCarli, Charles; Scott Turner, R.; Koeppe, Robert A.; Higdon, Roger; Minoshima, Satoshi.

In: Brain, Vol. 130, No. 10, 10.2007, p. 2616-2635.

Research output: Contribution to journalArticle

Foster, NL, Heidebrink, JL, Clark, CM, Jagust, WJ, Arnold, SE, Barbas, NR, DeCarli, C, Scott Turner, R, Koeppe, RA, Higdon, R & Minoshima, S 2007, 'FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease', Brain, vol. 130, no. 10, pp. 2616-2635. https://doi.org/10.1093/brain/awm177
Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007 Oct;130(10):2616-2635. https://doi.org/10.1093/brain/awm177
Foster, Norman L. ; Heidebrink, Judith L. ; Clark, Christopher M. ; Jagust, William J. ; Arnold, Steven E. ; Barbas, Nancy R. ; DeCarli, Charles ; Scott Turner, R. ; Koeppe, Robert A. ; Higdon, Roger ; Minoshima, Satoshi. / FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. In: Brain. 2007 ; Vol. 130, No. 10. pp. 2616-2635.
@article{addfb60f88e7490c820c0da7fe5df811,
title = "FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease",
abstract = "Distinguishing Alzheimer's disease (AD) and frontotemporal dementia (FTD) currently relies on a clinical history and examination, but positron emission tomography with [18F] fluorodeoxyglucose (FDG-PET) shows different patterns of hypometabolism in these disorders that might aid differential diagnosis. Six dementia experts with variable FDG-PET experience made independent, forced choice, diagnostic decisions in 45 patients with pathologically confirmed AD (n = 31) or FTD (n = 14) using five separate methods: (1) review of clinical summaries, (2) a diagnostic checklist alone, (3) summary and checklist, (4) transaxial FDG-PET scans and (5) FDG-PET stereotactic surface projection (SSP) metabolic and statistical maps. In addition, we evaluated the effect of the sequential review of a clinical summary followed by SSP. Visual interpretation of SSP images was superior to clinical assessment and had the best inter-rater reliability (mean kappa = 0.78) and diagnostic accuracy (89.6{\%}). It also had the highest specificity (97.6{\%}) and sensitivity (86{\%}), and positive likelihood ratio for FTD (36.5). The addition of FDG-PET to clinical summaries increased diagnostic accuracy and confidence for both AD and FTD. It was particularly helpful when raters were uncertain in their clinical diagnosis. Visual interpretation of FDG-PET after brief training is more reliable and accurate in distinguishing FTD from AD than clinical methods alone. FDG-PET adds important information that appropriately increases diagnostic confidence, even among experienced dementia specialists.",
keywords = "Alzheimer's disease, FDG, Frontotemporal dementia, PET",
author = "Foster, {Norman L.} and Heidebrink, {Judith L.} and Clark, {Christopher M.} and Jagust, {William J.} and Arnold, {Steven E.} and Barbas, {Nancy R.} and Charles DeCarli and {Scott Turner}, R. and Koeppe, {Robert A.} and Roger Higdon and Satoshi Minoshima",
year = "2007",
month = "10",
doi = "10.1093/brain/awm177",
language = "English (US)",
volume = "130",
pages = "2616--2635",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

AU - Foster, Norman L.

AU - Heidebrink, Judith L.

AU - Clark, Christopher M.

AU - Jagust, William J.

AU - Arnold, Steven E.

AU - Barbas, Nancy R.

AU - DeCarli, Charles

AU - Scott Turner, R.

AU - Koeppe, Robert A.

AU - Higdon, Roger

AU - Minoshima, Satoshi

PY - 2007/10

Y1 - 2007/10

N2 - Distinguishing Alzheimer's disease (AD) and frontotemporal dementia (FTD) currently relies on a clinical history and examination, but positron emission tomography with [18F] fluorodeoxyglucose (FDG-PET) shows different patterns of hypometabolism in these disorders that might aid differential diagnosis. Six dementia experts with variable FDG-PET experience made independent, forced choice, diagnostic decisions in 45 patients with pathologically confirmed AD (n = 31) or FTD (n = 14) using five separate methods: (1) review of clinical summaries, (2) a diagnostic checklist alone, (3) summary and checklist, (4) transaxial FDG-PET scans and (5) FDG-PET stereotactic surface projection (SSP) metabolic and statistical maps. In addition, we evaluated the effect of the sequential review of a clinical summary followed by SSP. Visual interpretation of SSP images was superior to clinical assessment and had the best inter-rater reliability (mean kappa = 0.78) and diagnostic accuracy (89.6%). It also had the highest specificity (97.6%) and sensitivity (86%), and positive likelihood ratio for FTD (36.5). The addition of FDG-PET to clinical summaries increased diagnostic accuracy and confidence for both AD and FTD. It was particularly helpful when raters were uncertain in their clinical diagnosis. Visual interpretation of FDG-PET after brief training is more reliable and accurate in distinguishing FTD from AD than clinical methods alone. FDG-PET adds important information that appropriately increases diagnostic confidence, even among experienced dementia specialists.

AB - Distinguishing Alzheimer's disease (AD) and frontotemporal dementia (FTD) currently relies on a clinical history and examination, but positron emission tomography with [18F] fluorodeoxyglucose (FDG-PET) shows different patterns of hypometabolism in these disorders that might aid differential diagnosis. Six dementia experts with variable FDG-PET experience made independent, forced choice, diagnostic decisions in 45 patients with pathologically confirmed AD (n = 31) or FTD (n = 14) using five separate methods: (1) review of clinical summaries, (2) a diagnostic checklist alone, (3) summary and checklist, (4) transaxial FDG-PET scans and (5) FDG-PET stereotactic surface projection (SSP) metabolic and statistical maps. In addition, we evaluated the effect of the sequential review of a clinical summary followed by SSP. Visual interpretation of SSP images was superior to clinical assessment and had the best inter-rater reliability (mean kappa = 0.78) and diagnostic accuracy (89.6%). It also had the highest specificity (97.6%) and sensitivity (86%), and positive likelihood ratio for FTD (36.5). The addition of FDG-PET to clinical summaries increased diagnostic accuracy and confidence for both AD and FTD. It was particularly helpful when raters were uncertain in their clinical diagnosis. Visual interpretation of FDG-PET after brief training is more reliable and accurate in distinguishing FTD from AD than clinical methods alone. FDG-PET adds important information that appropriately increases diagnostic confidence, even among experienced dementia specialists.

KW - Alzheimer's disease

KW - FDG

KW - Frontotemporal dementia

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=34848814460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848814460&partnerID=8YFLogxK

U2 - 10.1093/brain/awm177

DO - 10.1093/brain/awm177

M3 - Article

C2 - 17704526

AN - SCOPUS:34848814460

VL - 130

SP - 2616

EP - 2635

JO - Brain

JF - Brain

SN - 0006-8950

IS - 10

ER -